Adaptive Biotechnologies Corp Share price Adaptive Biotechnologies Corp (ADPT) USD0.0001 Sell: $6.95 Buy: $6.96 $0.53 (7.07%)
Full Answer
What is the upside for ADMA Biologics'stock?
Their forecasts range from $3.00 to $10.00. On average, they anticipate ADMA Biologics' stock price to reach $5.70 in the next twelve months. This suggests a possible upside of 328.6% from the stock's current price. View analysts' price targets for ADMA Biologics or view top-rated stocks among Wall Street analysts.
What is ADMA Biologics'Price targets for the next 12 months?
5 brokers have issued 12-month price objectives for ADMA Biologics' stock. Their forecasts range from $3.00 to $10.00. On average, they anticipate ADMA Biologics' stock price to reach $5.70 in the next twelve months. This suggests a possible upside of 328.6% from the stock's current price.
When is adaptive Biotechnologies'next quarterly earnings announcement?
Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, May 4th 2022. View our earnings forecast for Adaptive Biotechnologies. How were Adaptive Biotechnologies' earnings last quarter? Adaptive Biotechnologies Co. (NASDAQ:ADPT) announced its quarterly earnings data on Tuesday, February, 15th.
What is adaptive Biotechnologies?
About Adaptive Biotechnologies Adaptive Biotechnologies is a commercial-stage biotechnology company focused on translating the genetic language of the adaptive immune system into clinical products to diagnose and treat disease.
Is Adaptive Biotechnologies a good investment?
Adaptive Biotechnologies has received a consensus rating of Buy. The company's average rating score is 2.63, and is based on 5 buy ratings, 3 hold ratings, and no sell ratings.
Should I buy ADPT stock?
The consensus among 3 Wall Street analysts covering (NASDAQ: ADPT) stock is to Buy ADPT stock.
Is Adaptive Biotechnologies a public company?
The public market is bullish on Adaptive Biotechnologies. The biotech company started trading on the Nasdaq exchange under the symbol ADPT at $38 per share Thursday morning, up 90 percent from the $20 per share price it set Wednesday evening after raising $300 million its IPO.
When did Adaptive biotech go public?
June 27, 2019Adaptive common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2019 , under the ticker symbol “ADPT.” The offering is expected to close on July 1, 2019 , subject to the satisfaction of customary closing conditions. Goldman Sachs & Co.
When did Adaptive go public?
Adaptive went public in June 2019, closing up more than 100% at $40.30 a share on its first trading day, making it at the time in the top five IPO debuts that year, according to CNBC.
How many people work at Adaptive Biotechnologies?
The company had 858 full-time employees at the end of 2021, according to its annual filing with the SEC. Adaptive, which develops technology to assess the immune response, grew fast during the pandemic.
Should I buy or sell Adaptive Biotechnologies stock right now?
8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. Ther...
What is Adaptive Biotechnologies' stock price forecast for 2022?
8 brokerages have issued 1-year price targets for Adaptive Biotechnologies' stock. Their forecasts range from $7.50 to $50.00. On average, they exp...
How has Adaptive Biotechnologies' stock performed in 2022?
Adaptive Biotechnologies' stock was trading at $28.06 at the beginning of the year. Since then, ADPT shares have decreased by 75.2% and is now trad...
When is Adaptive Biotechnologies' next earnings date?
Adaptive Biotechnologies is scheduled to release its next quarterly earnings announcement on Wednesday, August 3rd 2022. View our earnings forecas...
How were Adaptive Biotechnologies' earnings last quarter?
Adaptive Biotechnologies Co. (NASDAQ:ADPT) issued its quarterly earnings results on Wednesday, May, 4th. The company reported ($0.44) EPS for the q...
What guidance has Adaptive Biotechnologies issued on next quarter's earnings?
Adaptive Biotechnologies issued an update on its FY 2022 earnings guidance on Monday, May, 16th. The company provided EPS guidance of for the perio...
Who are Adaptive Biotechnologies' key executives?
Adaptive Biotechnologies' management team includes the following people: Mr. Chad M. Robins M.B.A , M.B.A., Co-Founder, CEO & Chairman (Age 47,...
What is Chad Robins' approval rating as Adaptive Biotechnologies' CEO?
51 employees have rated Adaptive Biotechnologies CEO Chad Robins on Glassdoor.com . Chad Robins has an approval rating of 92% among Adaptive Biote...
Who are some of Adaptive Biotechnologies' key competitors?
Some companies that are related to Adaptive Biotechnologies include Ablynx (ABLYF) , Abcam (ABCM) , Novavax (NVAX) , Vir Biotechnology (VIR) ,...
About Adaptive Biotechnologies
Adaptive Biotechnologies Corp. engages in the development of an immune medicine platform. It harnesses the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its products and services include immunoSEQ, clonoSEQ, cellular therapy, and vaccines.
Adaptive Biotechnologies (NASDAQ:ADPT) Frequently Asked Questions
7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Adaptive Biotechnologies in the last twelve months. There are currently 2 hold ratings and 5 buy ratings for the stock.
Key Data Points
Primary metrics and data points about Adaptive Biotechnologies Corporation.
Environmental, Social, and Governance Rating
"B" score indicates good relative ESG performance and an above-average degree of transparency in reporting material ESG data publicly and privately. Scores range from AAA to D.
Adaptive Biotechnologies Insider Trading History Chart
This chart shows the insider buying and selling history at Adaptive Biotechnologies by year and by quarter.
Adaptive Biotechnologies Share Price & Price History
This chart shows the closing price history over time for ADPT up to the past year.
SEC Filings (Institutional Ownership Changes) for Adaptive Biotechnologies (NASDAQ:ADPT)
85.07% of Adaptive Biotechnologies stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.
About ADMA Biologics
ADMA Biologics, Inc. operates as a biopharmaceutical company, which is engaged in the manufacturing, marketing and developing specialty plasma-derived biologics. The firm operates through the following business segments: ADMA BioManufacturing, Plasma Collection Center, and Corporate.
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADMA Biologics in the last twelve months. There are currently 4 buy ratings and 1 strong buy rating for the stock.
Why is the selling price higher than the buying price?
This can occur temporarily for a variety of reasons; shortly before the market opens, after the market closes or because of extraordinary price volatility during the trading day.
Is a buy or sell trade on the London Stock Exchange?
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation. Trades priced above the mid-price at the time the trade is placed are labelled ...
Is a trade above the mid price a recommendation?
It should only be considered an indication and not a recommendation. Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.
AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild-to-Moderate COVID-19
VANCOUVER, British Columbia, February 11, 2022--AbCellera-Discovered Antibody, Bebtelovimab, Receives U.S. FDA Emergency Use Authorization for the Treatment of Mild to Moderate COVID-19
AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
VANCOUVER, British Columbia, February 11, 2022--AbCellera to Present Virtually at the 11th Annual SVB Leerink Global Healthcare Conference on February 17, 2022
Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
VANCOUVER, British Columbia, February 11, 2022--Lilly to Supply up to 600,000 Doses of AbCellera-Discovered Bebtelovimab to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatments
AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
VANCOUVER, British Columbia, January 27, 2022--AbCellera to Report Full Year 2021 Financial Results on February 24, 2022
Hedge Funds Are Buying AbCellera Biologics Inc. (ABCL)
After several tireless days we have finished crunching the numbers from nearly 900 13F filings issued by the elite hedge funds and other investment firms that we track at Insider Monkey, which disclosed those firms’ equity portfolios as of September 30th. The results of that effort will be put on display in this article, as […]
Resolute Advisors LLC Buys Shopify Inc, PowerShares QQQ Trust Ser 1, Snap Inc, Sells SPDR ..
Investment company Resolute Advisors LLC (Current Portfolio) buys Shopify Inc, PowerShares QQQ Trust Ser 1, Snap Inc, Naspers, DoorDash Inc, sells SPDR S&P Bank ETF, Grupo Financiero Galicia SA, NVIDIA Corp, Schwab U.S.
Orbimed Advisors Llc Buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, ..
New York, NY, based Investment company Orbimed Advisors Llc (Current Portfolio) buys Adagio Therapeutics Inc, Zimmer Biomet Holdings Inc, Biogen Inc, HCA Healthcare Inc, Erasca Inc, sells Prelude Therapeutics Inc, Aurinia Pharmaceuticals Inc, Ascendis Pharma A/S, Natera Inc, Anthem Inc during the 3-months ended 2021Q3, according to the most recent filings of the investment company, Orbimed Advisors Llc..
